Navigation Links
Ceremed's OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows
Date:5/13/2008

LOS ANGELES, May 13 /PRNewswire/ -- New soluble polymer material designed to stop bone bleeding in surgery improves bone fusion and healing, according to a new animal study just published in the Annals of Thoracic Surgery (ATS). The findings come on the heels of recently published research showing that the use of the new polymer may lower the risk of surgical infections.

Researchers from the Medical University of South Carolina at Charleston and Keck School of Medicine at the University of Southern California in Los Angeles compared the effects of a newly available polymer (Ostene(R)) and of bone wax on the bone's ability to heal following median sternotomy -- a procedure with which most open heart surgeries begin. There are approximately 640,000 such procedures performed in the United States each year, and the rate of post-operative sternal complications is estimated at 2% to 8%.

The study showed that the sternum heals faster and grows significantly stronger when treated with Ostene(R) than in the presence of bone wax, a material traditionally used to stop bone bleeding in surgically cut bone surfaces. Bone wax inhibited new bone formation and healing, creating areas of sternal non-union. By contrast, there was consistent bone fusion and normal healing in the sternums treated with Ostene(R).

The results suggest that the use of Ostene(R) in sternotomy instead of bone wax may help reduce the number of sternal complications, including sternal non-union following cardiac surgery. The use of Ostene(R)is likely to improve post-operative bone healing and patient recovery.

Bone wax, a beeswax-based product, is the most commonly used bone hemostasis material despite its well-documented side effects. Numerous studies have indicated that bone wax interferes with the body's ability to clear bacteria and increases the risk of hospital-acquired infections; as the new MUSC / USC study confirms, bone wax also inhibits bone growth and bone healing after surgery.

Ostene(R) offers an alternative to bone wax without the added risk. Ostene(R) is a sterile mixture of water-soluble alkylene oxide copolymers formulated into an affordable, easy-to-handle synthetic bone hemostasis material. The use of Ostene in cardiac surgery may help reduce serious post-operative complications, such as the separation of the sternum or sternal wound infection. Wax-like and malleable during application, the biomaterial dissolves rapidly and is eliminated from the body unmetabolized within days after surgery. Ostene(R) is used in cardiac, orthopedic, and oral surgery and in neurosurgery.

Ostene(R) is the only product specifically designed to stop bone bleeding in surgery that will not interfere with bone healing or increase the risk of surgical infections. Other applications under development include the use of Ostene(R) as a safe, soluble delivery vehicle for a variety of therapeutic agents, from antibiotics to bone growth stimulants for enhanced healing. Ostene(R) is authorized for sale both in the U.S. and in the European market.

Commenting on the study Ceremed's President and CEO Tadeusz Wellisz, M.D., said, "The results confirm the effectiveness and safety of Ostene. Building on our alkylene oxide copolymers' unique properties, we are currently developing the next generation of Ostene(R), otherwise known as AOC, available in various levels of viscosity, from paste to a hard solid. AOC has great potential as an inert, soluble carrier that delivers a broad range of therapeutic agents to bone defects, from antibiotics to growth stimulants, without increasing risk to patient. We are able to custom-manufacture compounds using each OEM proprietary material in combination with the AOC carrier."

About The Company:

Ceremed, Inc. is a privately held medical device corporation formed in 2002 by a surgeon and a group of scientists from the University of Southern California. The company has unique expertise and a portfolio of innovative proprietary technology in the field of soluble alkylene oxide copolymers (AOC). These copolymers have multiple medical applications, including bone hemostasis, porous implant coatings, and delivery systems for a variety of therapeutic agents.

For additional information about the Company or for an abstract of the study, please contact Danielle Nolan at 310-815-2125 or info@ceremed.com
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Tadeusz Wellisz http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=72918


'/>"/>
SOURCE Ceremed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
2. Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents
3. Gene Therapy Improves Vision in Patients with Congenital Retinal Disease
4. SuperGens DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine
5. Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder
6. Tailored Clopidogrel Dosing Improves PCI Outcomes
7. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
8. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
9. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
10. New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
11. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Business Report" report to their offering. ... This report analyzes the worldwide markets for Dental Implants ... Canada , Japan , ... , and Rest of World. Annual estimates and ...
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets has announced ... 2016" report to their offering. ... The IPF pipeline is very strong with a total of ... Co., Inc., Biogen and Sanofi are involved in the development of the ... one is in Phase III stage, 15 are in Phase II stage, ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , Latin America , and ... 2015 through 2022. Also, a six-year historic analysis is provided for these ...
Breaking Medicine Technology:
(Date:3/24/2017)... , ... March 24, 2017 , ... ... of inspiring stories about real people of God in congregations across the United ... Miller, a Presbyterian minister ordained in 1964 who has served congregations in seven ...
(Date:3/23/2017)... Greensboro, NC & Seattle, WA (PRWEB) , ... March 23, 2017 ... ... international public health emergency and now estimates that there could be four million Zika-related ... fastest growing epidemics to date with numbers of US cases reported per year skyrocketing ...
(Date:3/23/2017)... Houston, Texas (PRWEB) , ... March 23, 2017 , ... ... their 3rd location in the greater Houston Area. The new location is located at ... St. Luke’s Hospital in Springwoods Village. This newest location will provide patients living in ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) ... Gruene Road in Building 2. The clinic is the group’s second in New Braunfels ... opening the company’s second New Braunfels location brings things full circle for the group, ...
(Date:3/23/2017)... ... 23, 2017 , ... The IoT (Internet of Things) is revolutionizing the way ... impact on businesses and individual consumers alike. Laboratories can maximize their profit margin ... anywhere from $4 trillion to $11 trillion dollars by the year 2025. McKinsey expects ...
Breaking Medicine News(10 mins):